Additional medical experience with these drugs will provide important information about the benefits and limitations of complement inhibition with this disease
Additional medical experience with these drugs will provide important information about the benefits and limitations of complement inhibition with this disease. treatment for end stage disease of the kidneys, heart, liver, Porcn-IN-1 or lungs. Acute rejection events are associated with worse graft results, and AMR imparts a poorer prognosis compared to cellular rejection (1-3). AMR…